By Colin Kellaher Blueprint Medicines shares jumped more than 25% on Thursday after the precision-therapy company posted better-than-expected quarterly sales.
Blueprint Medicines Enters $1 25 Billion Financing Collaborations with Sixth Street and Royalty Pharma globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.